logo
  

Reata Pharma Stock Trading Halted As FDA Discusses Bardoxolone NDA - Quick Facts

Bopharmaceutical company Reata Pharmaceuticals, Inc. (RETA) announced Wednesday that Nasdaq has halted trading of the Company's common stock.

The U.S. Food and Drug Administration's (FDA) Cardiovascular and Renal Drugs Advisory Committee is meeting to review the Company's New Drug Application (NDA) for bardoxolone methyl for the treatment of patients with chronic kidney disease caused by Alport syndrome.

The Advisory Committee meeting is scheduled from 9:30 am to 5:00 pm ET today. The Prescription Drug User Fee Act date for completion of the review of the NDA for bardoxolone is February 25, 2022.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Teva Pharmaceuticals USA, Inc. has recalled one lot of platelet-reducing drug Anagrelide in the form of capsules due to dissolution test failure detected during routine stability testing, the U.S. Food and Drug Administration, or FDA, said in a statement. The U.S. Food and Drug Administration said it has taken steps to make available millions of cans of additional infant and specialty formula to U.S. consumers in the coming months. Under the agency's recent increased flexibilities, British nutrition products maker Kendal Nutricare will send about 2 million cans of infant formula under the Kendamil brand initially to U.S. beginning in June. Video streaming giant Netflix Inc. announced the availability of a variety of mobile games. Players can download the games directly from the Netflix mobile app. The new games include Dragon Up (East Side Games), Moonlighter (11 Bit Studios), Townsmen - A Kingdom Rebuilt (HandyGames), and Exploding Kittens - The Game (Exploding Kittens Digital).
Follow RTT